PubMed Health⌕ Search

Biomedical subjects

B Schürch

Publications and source records attributed to B Schürch.

9 recordsLinked to original sources
PubMed2000

[Neurogenic voiding disorders. Current status of diagnosis and therapy].

Treatment of the neurogenic voiding disorders which occur after spinal cord injury represents one of the most important challenges of rehabilitation. Inadequate management of neurogenic voiding disorders, especially of urinary incontinence, results in impaired quality of life. Moreover, inadequately treated neurogenic voiding disorders may result in medium and long-term renal complications and even death. Treatment of neurogenic disorders, whatever their origin (spinal cord injury, multiple sclerosis, Parkinson's disease), must take into account the gravity of the neurological disease, the potential risks for the upper urinary tract and the expected quality of life. Therefore, each patient must be considered as a separate entity and treated individually. Recent progress in the comprehension of the neurophysiology of the lower urinary tract and the neurophysiopathology of the neurogenic voiding disorders has been followed by the development of new diagnostic and therapeutic tools aimed at improving the patients' health and quality of life.

Humans↗
PubMed2000

[Bladder dysfunction after spinal and peripheral nerve lesions].

Disturbances in bladder function might occur as consequence of multiple neurological diseases involving any neurological pathways connecting the brain to the peripheral organ. Bladder dysfunction, especially resulting incontinence leads to impaired quality of life, if not adequately treated. Moreover, impaired voiding function might result in renal damage and finally in renal insufficiency. In this paper various causes of neurogenic bladder dysfunction, resulting from spinal cord disease or peripheral nerve damages are described. Neurogenic voiding disorders secondary to cortical lesions or diseases at the level of the basal ganglia or brainstem have been voluntarily omitted.

Diagnosis, Differential↗
PubMed1995

Malnutrition and behavioral development: the nutrition variable.

During the last 50 years, the perception of nutrition variables that affect behavioral development has shifted, as have the scientific hypotheses that were addressed, the design of the studies that were conducted, the nature and composition of the dietary supplements that were given and compared and the interpretation of outcomes. Methods of diagnosing malnutrition and identifying the populations at risk of becoming malnourished are reviewed in relation to nutrition interventions. Even in dietary supplementation studies it can be difficult to isolate specific nutrient effects because of associations and interactions among dietary components. These and other problems associated with the study of possible effects of dietary energy, protein and micronutrients, and of breast vs. formula feeding on human development are examined. Where dietary intake data, biochemical indicators or clinical symptoms strongly suggest that presence of a single nutrient deficiency, the appropriate action may continue to be food supplementation or fortification, until the corresponding nutrient deficiency has been rectified in the habitual diet; where the nature of the deficiency is less clear, supplementation trials and programs aimed at improving dietary diversity and quality in general are more likely to show effects on indicators of behavioral development.

Anthropometry↗
PubMed1980

In vivo behaviour of gamma globulin preparations.

Metabolic properties of standard gamma globulin (St-GG) and of several gamma globulin (GG) preparations for intravenous use were analyzed in radioactive tracer studies. The in vivo behaviour of St-GG was investigated in 16 probands and found to be comparable to that of normal IgG. The kinetics of the resorption of St-GG from intramuscular deposits, its elimination from the intravascular compartment and from the body were studied in 2 probands. Metabolic properties of GG preparations for intravenous use were compared with those of St-GG in 3-4 probands after simultaneous injection of 125I- and 131I-labelled tracer doses. Important differences in the half-times of intravascular survival, in the rates of catabolism and in the distribution in the body were noticed for most of the preparations for intravenous use except for an improved acid-treated (pH 4) GG, the in vivo behaviour of which was similar to that of St-GG.

Adult↗